Shots: The companies collaborated to identify targets for Otsuka’s therapeutics discovery programmes by leveraging PhoreMost’s expertise and next-generation phenotypic screening platform, SITESEEKER Otsuka will validate the novel targets identified in […]readmore
Shots: Tempus to receive milestones and royalties and has an option to fund part of product development programs in return of high royalty payments. Genmab and Tempus will jointly develop […]readmore
Copyright © 2020 Digiqole. All Right Reserved.